Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel: Viral Lymphoma

Explore the latest updates and expert interviews

The Lymphoma Channel on VJHemOnc is supported by Janssen Pharmaceuticals (a Johnson & Johnson Company), Takeda, Karyopharm Therapeutics and MorphoSys. The supporters have no influence over the production of the content.

Welcome to the Lymphoma Channel: focus on Viral Lymphoma

VJHemOnc is excited to share updates in the field of viral lymphoma with video interviews and roundtable discussions with leading experts. Discover discussions on risk factors for viral lymphoma, cellular therapies and more on The Viral Lymphoma Channel.

View Lymphoma Overview Page
Efficacy of CD45RA- T-cell infusion to treat infections in immunocompromised patients and EBV-LPDs 1:28
Efficacy of CD45RA- T-cell infusion to treat infections in immunocompromised patients and EBV-LPDs
Antonio Pérez-Martínez • 23 Apr 2023
Update on ALLELE: tab-cel in patients with EBV+ PTLD following alloSCT after rituximab failure 6:01
Update on ALLELE: tab-cel in patients with EBV+ PTLD following alloSCT after rituximab failure
Amer Beitinjaneh • 22 Feb 2023
Oral nanatinostat and valganciclovir for EBV-associated lymphomas 1:47
Oral nanatinostat and valganciclovir for EBV-associated lymphomas
Pierluigi Porcu
Dutch HOVON lymphoma study group update 2:36
Dutch HOVON lymphoma study group update
Pieternella Lugtenburg • 20 Jun 2019
Viral lymphomas: risk factors and treatments 8:24
Viral lymphomas: risk factors and treatments
Catherine Bollard et al. • 21 Sep 2018
Cellular therapy and drug access for viral lymphomas 9:57
Cellular therapy and drug access for viral lymphomas
Catherine Bollard et al. • 21 Sep 2018

The Lymphoma Channel on VJHemOnc is supported by Janssen Pharmaceuticals (a Johnson & Johnson Company), Takeda, Karyopharm Therapeutics and MorphoSys.

The supporters have no influence over the production of the content.

If you are interested in becoming a supporter of The Lymphoma Channel, please contact us.

The content of VJHemOnc is intended for healthcare professionals